Amylyx Pharmaceuticals, Inc. (AMLX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -36.88M | -27.9M | -30.37M | -25.25M | -39.82M | -59.01M | -41.57M | -66.58M | -489K | 13.55M | -5.17M | 8.61M |
| Operating CF Margin % | - | - | - | - | - | 8873.38% | -9992.79% | 6508.31% | -0.55% | 12.5% | -5.03% | 8.77% |
| Operating CF Growth % | 7.39% | 52.71% | 26.95% | 62.08% | -8043.97% | -535.45% | -704.22% | -873.38% | 90.36% | 127.27% | 88% | 118.53% |
| Net Income | -41.28M | -33M | -34.39M | -41.44M | -35.91M | -37.55M | -72.7M | -72.7M | -118.79M | 4.73M | 20.89M | 22.07M |
| Depreciation & Amortization | 98K | 108K | 120K | 141K | 156K | 160K | 221K | 208K | 315K | 301K | 302K | 281K |
| Stock-Based Compensation | 0 | 6.39M | 7.08M | 7.35M | 6.83M | 6.74M | 6.8M | 9.57M | 9.92M | 9.53M | 10.18M | 9.95M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 9.56M | -1.49M | -1.24M | -1.26M | 168K | -1.66M | 34.71M | 5.04M | 107.9M | -2.57M | -2.48M | -1.98M |
| Working Capital Changes | -5.26M | 92K | -1.94M | 9.96M | -11.07M | -26.7M | -10.6M | -8.7M | 164K | 1.56M | -34.06M | -21.71M |
| Change in Receivables | 0 | 50K | -85K | 205K | 147K | 980K | 2.24M | 16.56M | 19.7M | -11.07M | 4.85M | -16.53M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.25M | -26.48M | -14.01M | -19.33M |
| Change in Payables | 10K | 275K | -33K | -1.53M | 0 | 1.47M | -3.49M | -16.43M | -652K | 15.82M | -18.39M | 13.84M |
| Cash from Investing | 36.26M | 29.47M | 5.24M | 22.99M | -43.66M | 64.98M | 38.82M | -28.96M | 819K | 20.93M | -108.09M | 123.22M |
| Capital Expenditures | -4M | -86K | -24K | -17K | -11K | -20K | 19K | -89K | -67K | -356K | -357K | -278K |
| CapEx % of Revenue | - | - | - | - | - | -3.01% | 4.57% | -8.7% | 0.08% | 0.33% | 0.35% | 0.28% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -43.65M | 0 | -36.2M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.22M | -208K | 191.61M | -31K | 65.66M | 110K | 80K | 27K | 131K | 230K | 889K | 1.38M |
| Debt Issued (Net) | 0 | 0 | 191.11M | 0 | 65.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 7.16M | 256.69M | 2.66M | 72K | -885K | 0 | 0 | 0 | 1.45M | 347K | 984K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -885K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3.94M | -256.9M | -2.16M | -103K | 970K | 110K | 80K | 27K | -1.31M | -117K | -95K | 1.38M |
| Net Change in Cash | 2.48M | 1.48M | 167.09M | -1.68M | -17.62M | 5.56M | -2.44M | -95.55M | 351K | 34.94M | -112.5M | 133.2M |
| Free Cash Flow | -36.88M | -27.99M | -30.39M | -25.27M | -39.84M | -59.03M | -41.55M | -66.67M | -556K | 13.2M | -5.53M | 8.33M |
| FCF Margin % | - | - | - | - | - | 8876.39% | -9988.22% | 6517.01% | -0.63% | 12.17% | -5.38% | 8.48% |
| FCF Growth % | 7.41% | 52.58% | 26.86% | 62.1% | -7064.57% | -547.35% | -651.92% | -900.25% | 89.55% | 126.22% | 87.31% | 117.51% |
| FCF per Share | -0.33 | -0.30 | -0.33 | -0.28 | -0.46 | -0.86 | -0.61 | -0.98 | -0.01 | 0.19 | -0.08 | 0.12 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.85x | 0.88x | 0.61x | 1.11x | 1.57x | 0.57x | 0.92x | 0.00x | 2.86x | -0.25x | 0.39x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 444K | -17K | 6K | 0 | 0 | 0 | 2.56M |